Fig. 5
Effect of unsealed mitochondria in DMBA induced mammary carcinoma mouse. (A) Beginning at 5 weeks of age, female mice were given 1 mg of DMBA by oral gavage and 30 mg of subcutaneous pellets of MPA for 6 weeks. Mice with DMBA-induced mammary carcinoma were treated with doxorubicin or unsealed mitochondria γ. Doxorubicin was administered weekly by intraperitoneal injection (5 mg/kg or 0.05 mg/kg body weight) for 4 weeks. Unsealed mitochondria γ were administered weekly with 1 × 104 per gram of body weight via the tail vein. The arrow indicates the injection days. (B) Schemata of the experimental setup to generate unsealed mitochondria γ using nano size-microfluidic device. (C-D) Bar graph or images of tumor volume change for mice treated with doxorubicin or unsealed mitochondria. (E) M-mode echocardiographic images from mice with DMBA-induced mammary carcinoma treated with doxorubicin or unsealed mitochondria. (F-G) Fractional shortening and ejection fraction were determined from the M-mode images. (H) Mitochondria from tunneling nanotube-released Endo G promoted breast tumor cell apoptosis with increased cleaved caspase-3. Results are the means ± SE of 6 experiments in each group. *Significantly different from treatment of 0 mg/kg doxorubicin, P < 0.05. #Significantly different from treatment of 5 mg/kg doxorubicin, P < 0.05